XML 81 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 28, 2019
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
We generated net sales in the following geographic locations(1) (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 28,
2019
 
September 29,
2018
 
September 28,
2019
 
September 29,
2018
U.S.
$
785.9

 
$
739.0

 
$
2,323.2

 
$
2,297.7

Europe(2)
334.6

 
317.2

 
991.3

 
1,023.4

All other countries(3)
70.6

 
76.9

 
200.1

 
215.4

Total net sales
$
1,191.1

 
$
1,133.1

 
$
3,514.6

 
$
3,536.5


(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $5.2 million and $17.3 million for the three and nine months ended September 28, 2019, respectively, and $9.9 million and $20.3 million for the three and nine months ended September 29, 2018, respectively.
(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by product category (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 28,
2019
 
September 29,
2018
 
September 28,
2019
 
September 29,
2018
CSCA(1)
 
 
 
 
 
 
 
Cough/cold/allergy/sinus
$
125.8

 
$
113.8

 
$
379.3

 
$
364.6

Infant nutritionals
93.3

 
112.4

 
274.8

 
325.0

Analgesics
85.7

 
96.8

 
262.7

 
282.7

Gastrointestinal
83.0

 
95.4

 
289.5

 
290.6

Smoking cessation
77.1

 
72.8

 
220.9

 
209.9

Oral self-care
54.2

 
—

 
54.2

 
—

Natural health and vitamins, minerals and dietary supplements
3.3

 
5.0

 
10.6

 
12.3

Animal health
1.8

 
20.4

 
43.8

 
78.6

Other CSCA(2)
89.1

 
79.6

 
241.4

 
231.0

Total CSCA
613.3

 
596.2

 
1,777.2

 
1,794.7

CSCI
 
 
 
 
 
 
 
Cough/cold/allergy/sinus
93.4

 
94.8

 
263.2

 
278.2

Lifestyle
72.3

 
70.5

 
235.0

 
246.3

Personal care and derma-therapeutics
56.0

 
60.0

 
191.2

 
215.3

Natural health and vitamins, minerals and dietary supplements
31.0

 
32.2

 
86.4

 
93.3

Anti-parasites
26.8

 
30.2

 
79.5

 
88.7

Oral self-care
22.8

 
—

 
22.8

 
—

Other CSCI(3)
45.2

 
46.5

 
147.7

 
148.1

Total CSCI
347.5

 
334.2

 
1,025.8

 
1,069.9

RX
230.3

 
202.7

 
711.6

 
671.9

Total net sales
$
1,191.1

 
$
1,133.1

 
$
3,514.6

 
$
3,536.5


(1)    Includes net sales from our OTC contract manufacturing business.
(2)
Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.    
(3)
Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances
The following table provides information about contract assets from contracts with customers (in millions):
 
Balance Sheet Location
 
September 28,
2019
 
December 31,
2018
Short-term contract assets
Prepaid expenses and other current assets
 
$
25.8

 
$
25.5